Fig 1: Western blot experiments of CHST7, POU1F1, DLL3, and EIF2AK3. (A) Electrophoretic band of CHST7, POU1F1, DLL3, and EIF2AK3 in 8 patients. (B) Correlation analysis of CHST7 and POU1F1, DLL3, and EIF2AK3. In this study, the gray value of patient 1 as 1.
Fig 2: CHST7 is related to the tumor differentiation of PAs. (A) Correlation analysis of CHST7 and Pit-1 in 106 samples. (B) Correlation analysis of CHST7 and SSTR2 in 106 samples. (C) ROC curve of CHST7 for the Pit-1 lineage. (D) ROC curve of CHST7 for the TBX19 lineage. (E) ROC curve of CHST7 for the SF-1 lineage.
Fig 3: The mRNA levels of CHST7, transcription factors, and receptors grouped by different CHST7-promoter-methylation statuses. (A) CHST7. (B) Pit-1. (C) TBX19. (D) SF-1. (E) ESR1. (F) ESR2. (G) SSTR2. (H) SSTR5. Compared to the hypermethylation group: * p < 0.05; ** p < 0.01; *** p < 0.001.
Fig 4: INHBE is related to the tumor differentiation of PAs. (A) The correlation analysis of CHST7 and INHBC. (B) The correlation analysis of CHST7 and INHBE. (C) mRNA levels of INHBE in the three lineages. *** p < 0.001. (D) ROC curve of INHBE for the Pit-1 lineage. (E) ROC curve of INHBE for the TBX19 lineage. (F) ROC curve of INHBE for the SF-1 lineage.
Fig 5: The mRNA levels of transcription factors and receptors compared with different mRNA levels of CHST7. (A) Pit-1; (B) TBX19; (C) SF-1; (D) ESR1; (E) ESR2; (F) SSTR2; (G) SSTR5. Compared to the low-CHST7 group: * p < 0.05; ** p < 0.01; *** p < 0.001.
Supplier Page from Abcam for Anti-Pit1 antibody [EPR23555-203]